PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
7.72%
Positive EBIT growth while GNPX is negative. John Neff might see a substantial edge in operational management.
7.72%
Positive operating income growth while GNPX is negative. John Neff might view this as a competitive edge in operations.
12.50%
Positive net income growth while GNPX is negative. John Neff might see a big relative performance advantage.
15.94%
Positive EPS growth while GNPX is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
15.94%
Positive diluted EPS growth while GNPX is negative. John Neff might view this as a strong relative advantage in controlling dilution.
4.10%
Share count expansion well above GNPX's 1.06%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
4.10%
Diluted share count expanding well above GNPX's 0.87%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
-32.84%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-32.79%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-48098.63%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
-29341.33%
Both show negative mid-term OCF/share growth. Martin Whitman might suspect a challenged environment or large capital demands for both.
-23.11%
Both face negative short-term OCF/share growth. Martin Whitman would suspect macro or cyclical issues hitting them both.
-39968.68%
Negative 10Y net income/share CAGR while GNPX is at 89.37%. Joel Greenblatt sees a major red flag in long-term profit erosion.
-32.05%
Negative 5Y net income/share CAGR while GNPX is 89.37%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
-188.96%
Negative 3Y CAGR while GNPX is 89.37%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
7755.72%
Equity/share CAGR of 7755.72% while GNPX is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
2687.68%
Equity/share CAGR of 2687.68% while GNPX is zero. Bruce Berkowitz might see a minor advantage that could compound if the firm maintains positive net worth growth.
-9.18%
Negative 3Y equity/share growth while GNPX is at 0.00%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-28.88%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-33.82%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
No Data
No Data available this quarter, please select a different quarter.
-2.78%
Our R&D shrinks while GNPX invests at 53.56%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
-14.34%
We cut SG&A while GNPX invests at 57.61%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.